**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 58514

**Manuscript Type:** CORRECTION

**Erratum: Author’s Affiliation Correction. Type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor positive gastric cancer (World J Clin Cases 2019; Aug 6; 7 (15): 1964-1977)**

KaitoA *et al.*Correction to “HER2 heterogeneity is a poor prognosticator for HER2 positive gastric cancer”

Akio Kaito, Takeshi Kuwata, Masanori Tokunaga, Kohei Shitara, Reo Sato, Tetsuo Akimoto, Takahiro Kinoshita

**Akio Kaito, Masanori Tokunaga, Reo Sato, Takahiro Kinoshita,** Gastric Surgery Division, National Cancer Center Hospital East, Kashiwa 277-8577, Japan

**Akio Kaito, Takeshi Kuwata,** Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa 277-8577, Japan

**Akio Kaito, Kohei Shitara,** Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan

**Akio Kaito, Tetsuo Akimoto,** Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo 163-8001, Japan

**Takeshi Kuwata, Kohei Shitara,** Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center Hospital East, Kashiwa 277-8577, Japan

**Tetsuo Akimoto,** Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan

**Author contributions:** Kaito A and Kuwata T contributed equally to this correction; *i.e.,* study concepts, study design; all authors contributed equally to manuscript editing and manuscript review.

**Corresponding author: Takeshi Kuwata, MD, PhD, Doctor,** Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1, Kashiwano-ha, Kashiwa 277-8577, Japan. tkuwata@east.ncc.go.jp

**Received:** July 25, 2020

**Revised:** [September](javascript:;) 30, 2020

**Accepted:** October 20, 2020

**Published online:**

**Abstract**

Correction to "Type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor-positive gastric cancer" *World J Clin Cases* 2019; 7(15): 1964-1977. In this article, one of the affiliation of the first author was lacked. Akio Kaito, the first author, belonged to Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo 163-8001, Japan.

**Key Words:** Correction

Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. Erratum: Author’s Affiliation Correction. Type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor positive gastric cancer (*World J Clin Cases* 2019; Aug 6; 7 (15): 1964-1977). *World J Clin Cases* 2020; In press

**Core Tip:** This manuscript is an author's affiliation correction for type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor positive gastric cancer (*World J Clin Cases* 2019; Aug 6; 7 (15): 1964-1977).

**CORRECTION**

Correction to: Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. Type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor-positive gastric cancer. *World J Clin Cases* 2019; 7(15): 1964-1977 [PMID: 31423428 DOI: 10.12998/wjcc.v7.i15.1964].

In this article[1], one of the affiliation of the first author was lacked. Akio Kaito, the first author, belonged to Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo 163-8001, Japan. We apologize for the error.

**REFERENCES**

1 **Kaito A**, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. *World J Clin Cases* 2019; **7**: 1964-1977 [PMID: 31423428 DOI: 10.12998/wjcc.v7.i15.1964]

**Footnotes**

**Conflict-of-interest statement:** Not declared.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** July 25, 2020

**First decision:** September 24, 2020

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** Japan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**S-Editor:** Zhang L **L-Editor: P-Editor:**